- Home
- PCM vs QNCX Comparison
PCM vs QNCX Comparison
Compare PCM & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCM
- QNCX
- Stock Information
- Founded
- PCM 1993
- QNCX 2012
- Country
- PCM United States
- QNCX United States
- Employees
- PCM N/A
- QNCX N/A
- Industry
- PCM Trusts Except Educational Religious and Charitable
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCM Finance
- QNCX Health Care
- Exchange
- PCM Nasdaq
- QNCX Nasdaq
- Market Cap
- PCM 82.0M
- QNCX 88.6M
- IPO Year
- PCM N/A
- QNCX 2019
- Fundamental
- Price
- PCM $6.35
- QNCX $1.68
- Analyst Decision
- PCM
- QNCX Strong Buy
- Analyst Count
- PCM 0
- QNCX 4
- Target Price
- PCM N/A
- QNCX $7.75
- AVG Volume (30 Days)
- PCM 29.1K
- QNCX 350.1K
- Earning Date
- PCM 01-01-0001
- QNCX 11-12-2025
- Dividend Yield
- PCM 11.68%
- QNCX N/A
- EPS Growth
- PCM N/A
- QNCX N/A
- EPS
- PCM N/A
- QNCX N/A
- Revenue
- PCM N/A
- QNCX N/A
- Revenue This Year
- PCM N/A
- QNCX N/A
- Revenue Next Year
- PCM N/A
- QNCX N/A
- P/E Ratio
- PCM N/A
- QNCX N/A
- Revenue Growth
- PCM N/A
- QNCX N/A
- 52 Week Low
- PCM $6.88
- QNCX $0.72
- 52 Week High
- PCM $10.20
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PCM 46.17
- QNCX 46.91
- Support Level
- PCM $6.25
- QNCX $1.44
- Resistance Level
- PCM $6.39
- QNCX $1.84
- Average True Range (ATR)
- PCM 0.07
- QNCX 0.12
- MACD
- PCM 0.01
- QNCX -0.00
- Stochastic Oscillator
- PCM 70.76
- QNCX 50.57
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.